OpenAI Acquires Orchestra Bio to Expand Drug Development AI
Edited by Steinar Vigdel Kolnes, Editor, Oslo
OpenAI is bringing Orchestra Bio’s drug-development agents into Rosalind, its life sciences suite, according to Decrypt.
OpenAI has acquired Orchestra Bio, according to Decrypt, adding its drug-development AI agents to the company’s life sciences efforts.
The ChatGPT developer plans to integrate Orchestra’s agents into Rosalind, its life sciences suite. The move focuses on using AI to handle routine work involved in developing medicines.
OpenAI aims to shorten a process that can take more than a decade before a medicine reaches patients. The report did not provide evidence of time savings achieved through the integration.
Source: Decrypt
